S&P 500: 693.95 +0.5% NASDAQ 100: 614.32 +0.8% Dow Jones: 501.22 +0.0%

Charles River Laboratories International, Inc.

CRL Healthcare
$185.7 $-3.51 (-1.86%)
Market Cap: $9.14 B
Gurus Holding
7
Popularity Rank
#946
% of Shares Held
4.56%
Net Activity (Q3 2025)
+$10.9 M

Guru Ownership Trend

Guru Analysis for Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q3 2025, a total of 7 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $416.97 M.

Top institutional holders include John Rogers and Joel Greenblatt.

Institutional sentiment is currently Bullish. This is evidenced by a $10.9 M net inflow during the quarter.

Recent activity highlights Cliff Asness who increased their stake by 890.7%. Conversely, Paul Tudor Jones reduced exposure by 45.4%.

Key Holders

Top 5 by Value

$233.14 M
$49.4 M
$39.52 M
$14.51 M

Top 5 by Conviction

Recent Activity Breakdown (Q3 2025)

+$61.1 M
Total Buy Value
New Buys 1
Additions 4
-$50.2 M
Total Sell Value
Reductions 4
Sold Out 1

Guru Consensus (Q3 2025)

Based on recent activity
Net Sellers
5
Net Buyers
5

FAQs for Charles River Laboratories International, Inc. (CRL)

Major holders include John Rogers ($233.14 M), Joel Greenblatt ($49.4 M), Cliff Asness ($39.52 M). According to the latest reported data, 7 tracked investment managers collectively hold approximately 2.25 M shares.

According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $10.9 M, with 5 managers increasing positions and 5 managers reducing holdings.

During the most recent reporting period, 4 managers trimmed their positions, while 1 fully exited CRL. The total reported sell value was $50.2 M.

Yes, 1 managers opened new positions in CRL, and 4 increased their existing holdings. The total reported buy value was $61.1 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
2.49% Add 5.3% 1,490,098 $233.14 M Q3 2025
0.22% Add 17.3% 315,755 $49.4 M Q3 2025
0.03% Add 890.7% 265,083 $39.52 M Q3 2025
0.02% Reduce -45.4% 92,717 $14.51 M Q3 2025
0.11% Add 82.5% 48,925 $7.65 M Q3 2025
0.01% New Buy 19,908 $3.11 M Q3 2025
0.02% Reduce -42.0% 12,909 $2.02 M Q3 2025
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form